VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Fundamental Analysis
Europe - FRA:VX1 - US92532F1003 - Common Stock
330.35 EUR
+1.8 (+0.55%)
We assign a fundamental rating of 7 out of 10 to VX1. VX1 was compared to 75 industry peers in the Biotechnology industry. VX1 has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. VX1 is growing strongly while it is still valued neutral. This is a good combination! This makes VX1 very considerable for growth and quality investing!
1. Profitability
1.1 Basic Checks
VX1 had positive earnings in the past year.
In the past year VX1 had a positive cash flow from operations.
Of the past 5 years VX1 4 years were profitable.
Of the past 5 years VX1 4 years had a positive operating cash flow.
1.2 Ratios
The Return On Assets of VX1 (15.13%) is better than 88.00% of its industry peers.
With an excellent Return On Equity value of 21.18%, VX1 belongs to the best of the industry, outperforming 89.33% of the companies in the same industry.
VX1 has a Return On Invested Capital of 15.66%. This is amongst the best in the industry. VX1 outperforms 89.33% of its industry peers.
The Average Return On Invested Capital over the past 3 years for VX1 is above the industry average of 13.78%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.13% | ||
| ROE | 21.18% | ||
| ROIC | 15.66% |
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
1.3 Margins
Looking at the Profit Margin, with a value of 31.86%, VX1 belongs to the top of the industry, outperforming 88.00% of the companies in the same industry.
VX1's Operating Margin of 38.77% is amongst the best of the industry. VX1 outperforms 93.33% of its industry peers.
VX1's Operating Margin has improved in the last couple of years.
The Gross Margin of VX1 (86.11%) is better than 76.00% of its industry peers.
VX1's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 38.77% | ||
| PM (TTM) | 31.86% | ||
| GM | 86.11% |
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), VX1 is creating value.
The number of shares outstanding for VX1 has been reduced compared to 1 year ago.
Compared to 5 years ago, VX1 has less shares outstanding
VX1 has a better debt/assets ratio than last year.
2.2 Solvency
VX1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC1.64
WACC9.57%
2.3 Liquidity
A Current Ratio of 2.52 indicates that VX1 has no problem at all paying its short term obligations.
The Current ratio of VX1 (2.52) is comparable to the rest of the industry.
VX1 has a Quick Ratio of 2.16. This indicates that VX1 is financially healthy and has no problem in meeting its short term obligations.
VX1 has a Quick ratio (2.16) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.52 | ||
| Quick Ratio | 2.16 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 7966.67% over the past year.
The earnings per share for VX1 have been decreasing by -44.14% on average. This is quite bad
VX1 shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.46%.
VX1 shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.50% yearly.
EPS 1Y (TTM)7966.67%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%135.23%
Revenue 1Y (TTM)10.46%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%12.06%
3.2 Future
Based on estimates for the next years, VX1 will show a very strong growth in Earnings Per Share. The EPS will grow by 150.73% on average per year.
Based on estimates for the next years, VX1 will show a quite strong growth in Revenue. The Revenue will grow by 10.01% on average per year.
EPS Next Y6256.61%
EPS Next 2Y749.77%
EPS Next 3Y329.69%
EPS Next 5Y150.73%
Revenue Next Year10.03%
Revenue Next 2Y9.8%
Revenue Next 3Y9.48%
Revenue Next 5Y10.01%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 23.05, which indicates a rather expensive current valuation of VX1.
Based on the Price/Earnings ratio, VX1 is valued cheaper than 81.33% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.41, VX1 is valued at the same level.
The Price/Forward Earnings ratio is 18.64, which indicates a rather expensive current valuation of VX1.
82.67% of the companies in the same industry are more expensive than VX1, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.88, VX1 is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.05 | ||
| Fwd PE | 18.64 |
4.2 Price Multiples
VX1's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. VX1 is cheaper than 77.33% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, VX1 is valued a bit cheaper than the industry average as 80.00% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 28.6 | ||
| EV/EBITDA | 20.14 |
4.3 Compensation for Growth
VX1's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
VX1 has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as VX1's earnings are expected to grow with 329.69% in the coming years.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y749.77%
EPS Next 3Y329.69%
5. Dividend
5.1 Amount
VX1 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:VX1 (9/19/2025, 9:52:08 AM)
330.35
+1.8 (+0.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners97.63%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap84.70B
Analysts75.9
Price Target416.38 (26.04%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.87%
Min EPS beat(2)-7.2%
Max EPS beat(2)3.45%
EPS beat(4)2
Avg EPS beat(4)-0.78%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.69%
EPS beat(8)5
Avg EPS beat(8)-64.35%
EPS beat(12)7
Avg EPS beat(12)-42%
EPS beat(16)10
Avg EPS beat(16)-30.64%
Revenue beat(2)1
Avg Revenue beat(2)-2.37%
Min Revenue beat(2)-4.8%
Max Revenue beat(2)0.06%
Revenue beat(4)2
Avg Revenue beat(4)-0.57%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.87%
Revenue beat(12)5
Avg Revenue beat(12)-0.45%
Revenue beat(16)8
Avg Revenue beat(16)0.05%
PT rev (1m)-4.31%
PT rev (3m)-8.22%
EPS NQ rev (1m)0.13%
EPS NQ rev (3m)0.01%
EPS NY rev (1m)0.71%
EPS NY rev (3m)0.92%
Revenue NQ rev (1m)0.16%
Revenue NQ rev (3m)0.39%
Revenue NY rev (1m)0.45%
Revenue NY rev (3m)0.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.05 | ||
| Fwd PE | 18.64 | ||
| P/S | 8.77 | ||
| P/FCF | 28.6 | ||
| P/OCF | 26.02 | ||
| P/B | 5.83 | ||
| P/tB | 6.4 | ||
| EV/EBITDA | 20.14 |
EPS(TTM)14.33
EY4.34%
EPS(NY)17.72
Fwd EY5.36%
FCF(TTM)11.55
FCFY3.5%
OCF(TTM)12.69
OCFY3.84%
SpS37.69
BVpS56.68
TBVpS51.66
PEG (NY)0
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.13% | ||
| ROE | 21.18% | ||
| ROCE | 22.25% | ||
| ROIC | 15.66% | ||
| ROICexc | 23.06% | ||
| ROICexgc | 25.99% | ||
| OM | 38.77% | ||
| PM (TTM) | 31.86% | ||
| GM | 86.11% | ||
| FCFM | 30.65% |
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
ROICexc(3y)43.35%
ROICexc(5y)48.92%
ROICexgc(3y)62.02%
ROICexgc(5y)75.97%
ROCE(3y)24.89%
ROCE(5y)25.65%
ROICexcg growth 3Y-29.98%
ROICexcg growth 5Y-9.76%
ROICexc growth 3Y-22.64%
ROICexc growth 5Y-1.94%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
F-Score6
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 173.52% | ||
| Cap/Sales | 3.04% | ||
| Interest Coverage | 260.41 | ||
| Cash Conversion | 83.13% | ||
| Profit Quality | 96.21% | ||
| Current Ratio | 2.52 | ||
| Quick Ratio | 2.16 | ||
| Altman-Z | N/A |
F-Score6
WACC9.57%
ROIC/WACC1.64
Cap/Depr(3y)171.61%
Cap/Depr(5y)187.83%
Cap/Sales(3y)3.11%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7966.67%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%135.23%
EPS Next Y6256.61%
EPS Next 2Y749.77%
EPS Next 3Y329.69%
EPS Next 5Y150.73%
Revenue 1Y (TTM)10.46%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%12.06%
Revenue Next Year10.03%
Revenue Next 2Y9.8%
Revenue Next 3Y9.48%
Revenue Next 5Y10.01%
EBIT growth 1Y4.24%
EBIT growth 3Y16.47%
EBIT growth 5Y29.7%
EBIT Next Year816.11%
EBIT Next 3Y130.8%
EBIT Next 5Y68.38%
FCF growth 1Y-9.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.45%
OCF growth 3YN/A
OCF growth 5YN/A